Haisco Pharmaceutical Group Co., Ltd.
002653
Rang in aandelen
#2010
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Aandeelprijs
$9.03
Marktkapitalisatie
$10.30B
Verandering (1 dag)
4.55%
Verandering (1 jaar)
24.15%
Land
CN
Handel Haisco Pharmaceutical Group Co., Ltd. (002653)
Categorie
Healthcare
Winst voor Haisco Pharmaceutical Group Co., Ltd. (002653)
Winst in Jun 2026 TTM: $144.70M
Volgens de meest recente financiële verslagen van Haisco Pharmaceutical Group Co., Ltd. bedraagt de huidige winst van het bedrijf $144.70M. In 2023 behaalde het bedrijf een winst van $42.74M, een daling ten opzichte van de winst van 2022, die $53.15M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Haisco Pharmaceutical Group Co., Ltd. van 2008 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $144.70M | 128.15% |
| 2024 | $63.43M | 48.41% |
| 2023 | $42.74M | -19.59% |
| 2022 | $53.15M | -33.86% |
| 2021 | $80.36M | -23.86% |
| 2020 | $105.54M | 34.49% |
| 2019 | $78.47M | 67.09% |
| 2018 | $46.96M | 18.07% |
| 2017 | $39.78M | -42.90% |
| 2016 | $69.65M | 8.93% |
| 2015 | $63.94M | -21.50% |
| 2014 | $81.46M | -13.14% |
| 2013 | $93.78M | 21.75% |
| 2012 | $77.03M | 31.46% |
| 2011 | $58.59M | 6.29% |
| 2010 | $55.13M | 19.25% |
| 2009 | $46.23M | 45.27% |
| 2008 | $31.82M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | 3,545.32% |
US
|
|
| $-3.09B | -2,233.33% |
US
|
|
| $-4.02B | -2,875.47% |
AU
|
|
| $1.95B | 1,248.04% |
NL
|
|
| - | - |
CH
|
